Simultaneous Determination of A Novel Antitrypanosomal Compound (OSU-36) and its Ester Derivative (OSU-40) in Plasma by HPLC: Application to First Pharmacokinetic Study in Rats

Purpose. To develop an HPLC-UV method for determination of a novel antitrypanosomal compound (OSU-36) and its ester prodrug (OSU-40) in rat plasma and to apply the method for pharmacokinetic evaluation of both compounds in rats. Methods. Since an attempt to assay for OSU-36 and OSU-40 in non-stabili...

Full description

Bibliographic Details
Main Authors: Pavel Gershkovich, Kishor M. Wasan, Olena Sivak, Summer Lysakowski, Carolyn Reid, Kokku Premalatha, Karl A. Werbovetz
Format: Article
Language:English
Published: Canadian Society for Pharmaceutical Sciences 2011-01-01
Series:Journal of Pharmacy & Pharmaceutical Sciences
Online Access:https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/9374
id doaj-a24d6a1d2567454d8da1cfd9620625a0
record_format Article
spelling doaj-a24d6a1d2567454d8da1cfd9620625a02020-11-25T04:06:04ZengCanadian Society for Pharmaceutical SciencesJournal of Pharmacy & Pharmaceutical Sciences1482-18262011-01-0114110.18433/J3CP4SSimultaneous Determination of A Novel Antitrypanosomal Compound (OSU-36) and its Ester Derivative (OSU-40) in Plasma by HPLC: Application to First Pharmacokinetic Study in RatsPavel Gershkovich0Kishor M. WasanOlena SivakSummer LysakowskiCarolyn ReidKokku PremalathaKarl A. WerbovetzUniversity of British ColumbiaPurpose. To develop an HPLC-UV method for determination of a novel antitrypanosomal compound (OSU-36) and its ester prodrug (OSU-40) in rat plasma and to apply the method for pharmacokinetic evaluation of both compounds in rats. Methods. Since an attempt to assay for OSU-36 and OSU-40 in non-stabilized plasma resulted in highly non-linear calibration curves and poor sensitivity due to instability of the compounds, the plasma was stabilized using paraoxon and ascorbic acid. The sample treatment included protein precipitation by acetonitrile; evaporation; reconstitution with acetonitrile and filtration. The chromatography conditions included Xterra RP18 3.5µm 4.6X100mm column and gradient mobile phase system of acetonitrile-water. Results. The limits of quantification (LOQ) were 50 ng/mL and 40 ng/mL for OSU-36 and OSU-40, respectively. The intra- and interday precision and accuracies were below 13% for low, medium and high quality control samples for both compounds. While OSU-40 has been stable in all tested handling conditions, OSU-36 was unstable in plasma after 20 days storage in -80°C or 4h 28°C storage. The developed method has been applied for a pharmacokinetic study in rats which revealed that an ester prodrug OSU-40 is rapidly converted to OSU-36 within the plasma compartment by plasma esterases. OSU-36, in turn, relatively quickly undergoes oxidative metabolism, including within the plasma compartment. Conclusions. A supplementation of rat plasma with an esterase inhibitor to prevent degradation of ester prodrug (OSU-40), and with antioxidant to prevent oxidation of OSU-36, is necessary for reliable determination of both compounds. Due to limited stability of OSU-36 in stabilized rat plasma, long-term storage of samples or prolonged handling in room temperature conditions is not recommended.https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/9374
collection DOAJ
language English
format Article
sources DOAJ
author Pavel Gershkovich
Kishor M. Wasan
Olena Sivak
Summer Lysakowski
Carolyn Reid
Kokku Premalatha
Karl A. Werbovetz
spellingShingle Pavel Gershkovich
Kishor M. Wasan
Olena Sivak
Summer Lysakowski
Carolyn Reid
Kokku Premalatha
Karl A. Werbovetz
Simultaneous Determination of A Novel Antitrypanosomal Compound (OSU-36) and its Ester Derivative (OSU-40) in Plasma by HPLC: Application to First Pharmacokinetic Study in Rats
Journal of Pharmacy & Pharmaceutical Sciences
author_facet Pavel Gershkovich
Kishor M. Wasan
Olena Sivak
Summer Lysakowski
Carolyn Reid
Kokku Premalatha
Karl A. Werbovetz
author_sort Pavel Gershkovich
title Simultaneous Determination of A Novel Antitrypanosomal Compound (OSU-36) and its Ester Derivative (OSU-40) in Plasma by HPLC: Application to First Pharmacokinetic Study in Rats
title_short Simultaneous Determination of A Novel Antitrypanosomal Compound (OSU-36) and its Ester Derivative (OSU-40) in Plasma by HPLC: Application to First Pharmacokinetic Study in Rats
title_full Simultaneous Determination of A Novel Antitrypanosomal Compound (OSU-36) and its Ester Derivative (OSU-40) in Plasma by HPLC: Application to First Pharmacokinetic Study in Rats
title_fullStr Simultaneous Determination of A Novel Antitrypanosomal Compound (OSU-36) and its Ester Derivative (OSU-40) in Plasma by HPLC: Application to First Pharmacokinetic Study in Rats
title_full_unstemmed Simultaneous Determination of A Novel Antitrypanosomal Compound (OSU-36) and its Ester Derivative (OSU-40) in Plasma by HPLC: Application to First Pharmacokinetic Study in Rats
title_sort simultaneous determination of a novel antitrypanosomal compound (osu-36) and its ester derivative (osu-40) in plasma by hplc: application to first pharmacokinetic study in rats
publisher Canadian Society for Pharmaceutical Sciences
series Journal of Pharmacy & Pharmaceutical Sciences
issn 1482-1826
publishDate 2011-01-01
description Purpose. To develop an HPLC-UV method for determination of a novel antitrypanosomal compound (OSU-36) and its ester prodrug (OSU-40) in rat plasma and to apply the method for pharmacokinetic evaluation of both compounds in rats. Methods. Since an attempt to assay for OSU-36 and OSU-40 in non-stabilized plasma resulted in highly non-linear calibration curves and poor sensitivity due to instability of the compounds, the plasma was stabilized using paraoxon and ascorbic acid. The sample treatment included protein precipitation by acetonitrile; evaporation; reconstitution with acetonitrile and filtration. The chromatography conditions included Xterra RP18 3.5µm 4.6X100mm column and gradient mobile phase system of acetonitrile-water. Results. The limits of quantification (LOQ) were 50 ng/mL and 40 ng/mL for OSU-36 and OSU-40, respectively. The intra- and interday precision and accuracies were below 13% for low, medium and high quality control samples for both compounds. While OSU-40 has been stable in all tested handling conditions, OSU-36 was unstable in plasma after 20 days storage in -80°C or 4h 28°C storage. The developed method has been applied for a pharmacokinetic study in rats which revealed that an ester prodrug OSU-40 is rapidly converted to OSU-36 within the plasma compartment by plasma esterases. OSU-36, in turn, relatively quickly undergoes oxidative metabolism, including within the plasma compartment. Conclusions. A supplementation of rat plasma with an esterase inhibitor to prevent degradation of ester prodrug (OSU-40), and with antioxidant to prevent oxidation of OSU-36, is necessary for reliable determination of both compounds. Due to limited stability of OSU-36 in stabilized rat plasma, long-term storage of samples or prolonged handling in room temperature conditions is not recommended.
url https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/9374
work_keys_str_mv AT pavelgershkovich simultaneousdeterminationofanovelantitrypanosomalcompoundosu36anditsesterderivativeosu40inplasmabyhplcapplicationtofirstpharmacokineticstudyinrats
AT kishormwasan simultaneousdeterminationofanovelantitrypanosomalcompoundosu36anditsesterderivativeosu40inplasmabyhplcapplicationtofirstpharmacokineticstudyinrats
AT olenasivak simultaneousdeterminationofanovelantitrypanosomalcompoundosu36anditsesterderivativeosu40inplasmabyhplcapplicationtofirstpharmacokineticstudyinrats
AT summerlysakowski simultaneousdeterminationofanovelantitrypanosomalcompoundosu36anditsesterderivativeosu40inplasmabyhplcapplicationtofirstpharmacokineticstudyinrats
AT carolynreid simultaneousdeterminationofanovelantitrypanosomalcompoundosu36anditsesterderivativeosu40inplasmabyhplcapplicationtofirstpharmacokineticstudyinrats
AT kokkupremalatha simultaneousdeterminationofanovelantitrypanosomalcompoundosu36anditsesterderivativeosu40inplasmabyhplcapplicationtofirstpharmacokineticstudyinrats
AT karlawerbovetz simultaneousdeterminationofanovelantitrypanosomalcompoundosu36anditsesterderivativeosu40inplasmabyhplcapplicationtofirstpharmacokineticstudyinrats
_version_ 1724432595479953408